Yann Echelard, Director at TG Therapeutics TGTX, disclosed an insider sell on June 16, according to a recent SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Echelard sold 10,000 shares of TG Therapeutics. The total transaction amounted to $369,400.
In the Tuesday’s morning session, TG Therapeutics‘s shares are currently trading at $35.05, experiencing a down of 1.63%.
Unveiling the Story Behind TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Financial Milestones: TG Therapeutics’s Journey
Positive Revenue Trend: Examining TG Therapeutics’s financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 90.4% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
-
Gross Margin: Achieving a high gross margin of 87.14%, the company performs well in terms of cost management and profitability within its sector.
-
Earnings per Share (EPS): TG Therapeutics’s EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.03.
Debt Management: TG Therapeutics’s debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
Financial Valuation Breakdown:
-
Price to Earnings (P/E) Ratio: TG Therapeutics’s stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 142.52.
-
Price to Sales (P/S) Ratio: The current P/S ratio of 15.17 is above industry norms, reflecting an elevated valuation for TG Therapeutics’s stock and potential overvaluation based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): TG Therapeutics’s EV/EBITDA ratio of 78.48 exceeds industry averages, indicating a premium valuation in the market
Market Capitalization: Indicating a reduced size compared to industry averages, the company’s market capitalization poses unique challenges.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Within the legal framework, an “insider” is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
Cracking Transaction Codes
Delving into transactions, investors typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of TG Therapeutics’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Add Comment